AL-ADTRAN
25.5.2023 14:01:33 CEST | Business Wire | Press release
Adtran today launched its FSP 3000 Edge OLS, an open line system designed for the new generation of coherent edge access, aggregation and metro networks. It enables operators to efficiently address soaring bandwidth demand from mobile, broadband and enterprise applications by leveraging the latest coherent pluggable technology in this cost-sensitive part of the network. The FSP 3000 Edge OLS has been specifically engineered for the use of coherent transmission at the optical edge, including the recently introduced Coherent 100ZR, as well as 400ZR optics. By utilizing power-optimized wavelength broadcasting technology and a gridless architecture, the solution enables a simple and affordable optical layer with compact and flexible nodes that can transport any coherent signal and baud rate.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230525005466/en/
Adtran’s FSP 3000 Edge OLS will help operators deploy coherent optical edge networks in the most effective way possible. (Graphic: Business Wire)
“At OFC, we showcased our world-first QSFP28 Coherent 100ZR, bringing robust, efficient and simple coherent technology to the edge of the network. Now we’re complementing this innovative transceiver with an OLS optimized for the cost-efficient transport of coherent technology at the optical edge. Providing maximum performance, it meets all critical demands of edge aggregation networks, including scalability, compact design, low power consumption, operational simplicity and extended temperature operation for outdoor deployment,” said Christoph Glingener, CTO at Adtran. “Our pioneering work at the network edge is creating whole new opportunities for service providers.”
The Adtran FSP 3000 Edge OLS is an open line system engineered to help operators roll out coherent optical edge networks in the most cost-effective and flexible way possible. With ZR-optimized technology for minimal insertion loss, the new OLS enables the use of ZR coherent optics at the optical edge in multiple use cases, including linear, hub-and-spoke or tree topologies. With its modular design, it empowers users to mix and match elements to create a solution that meets their exact needs. What’s more, the Adtran FSP 3000 Edge OLS facilitates the development of a compact and efficient optical layer with low-power nodes that require minimal space and can function in an extended temperature range. This enables deployment in outdoor environments, such as street cabinets.
“Our FSP 3000 Edge OLS offers a major boost to operators looking for an affordable way to tackle relentless growth in data traffic. Low-cost yet highly flexible, it can scale to transparently accommodate any line speed or baud rate. Now there’s a clear route to deploying an optical layer that leverages coherent transport technology, including 100ZR and 400ZR optics, and meets the stringent requirements of the new optical edge,” commented Henning Hinderthür, VP of product line management, Optical Networks at Adtran. “Our FSP 3000 Edge OLS harnesses advanced wavelength broadcast technology for new levels of power and cost efficiency. It’s also ready to be deployed anywhere from central offices to street furniture.”
Further details on Adtran’s FSP 3000 Edge OLS are available in these slides.
A supporting product video is available to watch.
A solution brief can also be downloaded.
About Adtran
ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.
Published by
ADTRAN Holdings, Inc.
www.adtran.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230525005466/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom